Lung Cancer | Topics

FDA Grants Breakthrough Therapy Designation to Tiragolumab Combo for PD-L1-High NSCLC
January 05, 2021

The combination of tiragolumab and atezolizumab (Tecentriq) was granted breakthrough therapy designation based on promising efficacy and safety data observed in the phase 2 CITYSCAPE trial.

FDA Grants Priority Review to sNDA for Lorlatinib in Previously Untreated ALK+ NSCLC
January 04, 2021

Under the FDA’s Real-Time Oncology Review Pilot Program and Project ORBIS, the FDA is reviewing a supplemental new drug application for lorlatinib (Lorbrena) as a first-line treatment for patients with ALK-positive metastatic non–small cell lung cancer.

Jennifer W. Carlisle, MD, Offers Perspective on Lung Cancer Advances in 2020
December 22, 2020

The Emory University Winship Cancer Institute expert discussed FDA approvals and other treatment advances that occurred this year.